Show simple item record

dc.contributor.authorLinch, M
dc.contributor.authorAttard, G
dc.date.accessioned2018-02-16T15:50:10Z
dc.date.issued2018-02
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2018, 29 (2), pp. 290 - 292
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1232
dc.identifier.eissn1569-8041
dc.identifier.doi10.1093/annonc/mdx785
dc.formatPrint
dc.format.extent290 - 292
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectAndrostenes
dc.subjectPrednisone
dc.subjectProspective Studies
dc.subjectCell Cycle
dc.subjectCell Proliferation
dc.subjectMale
dc.subjectGenome-Wide Association Study
dc.subjectWnt Signaling Pathway
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectAbiraterone Acetate
dc.titleProstate cancers that 'Wnt' respond to abiraterone.
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdx785
rioxxterms.licenseref.startdate2018-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume29
pubs.embargo.termsNot known
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record